Novo Nordisk Receives European Regulator's Positive Opinion for Higher Dose of Wegovy

MT Newswires Live12-12 22:56

Novo Nordisk (NVO) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the higher 7.2-milligram dose of its weight-loss drug Wegovy or semaglutide.

The positive opinion was based on two trials, where the higher dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes, the company said. The safety and tolerability profile is consistent with the approved 2.4 mg dose, Novo Nordisk added.

The 7.2 mg Wegovy dose could be available early in 2026, pending the European Commission's final approval, said Novo Nordisk executive vice president Ludovic Helfgott.

Novo Nordisk said the 7.2 mg Wegovy dose is also under review in the US, UK, and other countries.

Price: 50.46, Change: +0.16, Percent Change: +0.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590507856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590507856","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Receives European Regulator's Positive Opinion for Higher Dose of Wegovy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the higher 7.2-milligram dose of its weight-loss drug Wegovy or semaglutide.</p><p>The positive opinion was based on two trials, where the higher dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes, the company said. The safety and tolerability profile is consistent with the approved 2.4 mg dose, Novo Nordisk added.</p><p>The 7.2 mg Wegovy dose could be available early in 2026, pending the European Commission's final approval, said Novo Nordisk executive vice president Ludovic Helfgott.</p><p>Novo Nordisk said the 7.2 mg Wegovy dose is also under review in the US, UK, and other countries.</p><p>Price: 50.46, Change: +0.16, Percent Change: +0.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Receives European Regulator's Positive Opinion for Higher Dose of Wegovy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Receives European Regulator's Positive Opinion for Higher Dose of Wegovy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-12 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the higher 7.2-milligram dose of its weight-loss drug Wegovy or semaglutide.</p><p>The positive opinion was based on two trials, where the higher dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes, the company said. The safety and tolerability profile is consistent with the approved 2.4 mg dose, Novo Nordisk added.</p><p>The 7.2 mg Wegovy dose could be available early in 2026, pending the European Commission's final approval, said Novo Nordisk executive vice president Ludovic Helfgott.</p><p>Novo Nordisk said the 7.2 mg Wegovy dose is also under review in the US, UK, and other countries.</p><p>Price: 50.46, Change: +0.16, Percent Change: +0.33</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590507856","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590507856","pubTimestamp":1765551370,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the higher 7.2-milligram dose of its weight-loss drug Wegovy or semaglutide.The positive opinion was based on two trials, where the higher dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes, the company said. The safety and tolerability profile is consistent with the approved 2.4 mg dose, Novo Nordisk added.The 7.2 mg Wegovy dose could be available early in 2026, pending the European Commission's final approval, said Novo Nordisk executive vice president Ludovic Helfgott.Novo Nordisk said the 7.2 mg Wegovy dose is also under review in the US, UK, and other countries.Price: 50.46, Change: +0.16, Percent Change: +0.33","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","NVO":"诺和诺德","BK7104":"黄金","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO.AU":"NOVO RESOURCES CORP-CDI","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药"},"translate_title":"诺和诺德获得欧洲监管机构对更高剂量Wegovy的积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"NVO.AU":1},"content_text":"Novo Nordisk (NVO) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the higher 7.2-milligram dose of its weight-loss drug Wegovy or semaglutide.The positive opinion was based on two trials, where the higher dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes, the company said. The safety and tolerability profile is consistent with the approved 2.4 mg dose, Novo Nordisk added.The 7.2 mg Wegovy dose could be available early in 2026, pending the European Commission's final approval, said Novo Nordisk executive vice president Ludovic Helfgott.Novo Nordisk said the 7.2 mg Wegovy dose is also under review in the US, UK, and other countries.Price: 50.46, Change: +0.16, Percent Change: +0.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590507856","isCrawlerRequest":true}